What is Sotera Health's operating income?

Sotera Health's total operating income in 2025 was $362.03 million, based on the following breakdown: Total Gross Profit: $645.53 million Total Operating Expenses: $283.50 million

Sotera Health (SHC) Financials

$19.22 +0.22 (+1.16%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$19.22 0.00 (0.00%)

As of 05:51 AM Eastern

Compare

Annual Income Statements for Sotera Health

This table shows Sotera Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-21	-39	117	-375	51	44	78
Consolidated Net Income / (Loss)	-20	-37	117	-375	51	44	78
Net Income / (Loss) Continuing Operations	-20	-37	117	-375	51	44	78
Total Pre-Tax Income	-0.92	-39	176	-243	106	114	148
Total Operating Income	184	206	257	248	277	298	362
Total Gross Profit	395	444	519	557	577	602	646
Total Revenue	778	818	931	0.00	1,049	1,100	1,164
Operating Revenue	778	818	931	-	1,049	1,100	1,164
Total Cost of Revenue	383	375	413	447	472	498	518
Operating Cost of Revenue	383	375	413	56	472	498	518
Total Operating Expenses	212	238	262	246	300	305	284
Selling, General & Admin Expense	147	179	198	246	237	243	253
Amortization Expense	59	59	64	-	64	62	31
Total Other Income / (Expense), net	-185	-245	-81	-83	-171	-184	-215
Interest Expense	30	44	21	-	0.00	24	1.46
Interest & Investment Income	-158	-215	-74	-90	-143	-165	-156
Other Income / (Expense), net	3.38	15	14	6.30	-28	5.11	-57
Income Tax Expense	20	-1.37	59	-9.54	55	69	70
Basic Earnings per Share	($0.09)	($0.16)	$0.41	($0.83)	$0.18	$0.16	$0.27
Weighted Average Basic Shares Outstanding	232.40M	237.70M	279.23M	280.10M	281.01M	282.78M	283.96M
Diluted Earnings per Share	($0.09)	($0.16)	$0.41	($0.83)	$0.18	$0.16	$0.27
Weighted Average Diluted Shares Outstanding	232.40M	237.70M	279.38M	280.10M	283.22M	284.91M	286.42M
Weighted Average Basic & Diluted Shares Outstanding	-	-	282.93M	282.42M	282.83M	283.47M	284.39M

This table shows Sotera Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	39	6.32	8.75	17	12	-13	7.96	48	35	27	54
Consolidated Net Income / (Loss)	74	6.32	8.75	17	12	-13	7.96	48	35	27	54
Net Income / (Loss) Continuing Operations	74	6.32	8.75	17	12	-13	7.96	48	35	27	54
Total Pre-Tax Income	66	11	15	43	45	-15	19	73	70	43	78
Total Operating Income	104	53	77	81	87	57	88	111	170	76	107
Total Gross Profit	180	127	153	158	164	135	167	178	166	147	178
Total Revenue	310	248	277	285	290	255	294	311	303	280	321
Operating Revenue	310	248	277	285	290	255	294	311	303	280	321
Total Cost of Revenue	130	121	124	127	126	119	128	134	138	133	143
Operating Cost of Revenue	130	121	124	127	126	119	128	134	138	133	143
Total Operating Expenses	76	74	76	78	77	78	78	66	-4.41	71	71
Selling, General & Admin Expense	60	58	61	62	62	63	69	63	58	68	68
Amortization Expense	16	16	15	16	15	15	9.30	3.09	3.02	3.03	3.02
Total Other Income / (Expense), net	-3.35	-42	-62	-38	-42	-72	-70	-38	-100	-33	-29
Interest Expense	-	-	23	0.07	-	-	0.08	1.09	-	-	0.94
Interest & Investment Income	-43	-42	-40	-42	-41	-41	-41	-39	-35	-35	-34
Other Income / (Expense), net	39	-0.39	2.13	3.89	-0.52	-31	-29	1.99	-64	1.53	6.60
Income Tax Expense	27	4.69	6.39	26	33	-1.56	11	25	36	16	24
Basic Earnings per Share	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09	$0.19
Weighted Average Basic Shares Outstanding	281.01M	281.91M	282.89M	283.06M	282.78M	283.56M	283.93M	284.07M	283.96M	284.89M	285.77M
Diluted Earnings per Share	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09	$0.19
Weighted Average Diluted Shares Outstanding	283.22M	284.06M	284.54M	285.56M	284.91M	283.56M	285.76M	286.75M	286.42M	287.62M	288.15M
Weighted Average Basic & Diluted Shares Outstanding	282.83M	283.07M	283.21M	283.24M	283.47M	283.86M	284.05M	284.09M	284.39M	285.17M	285.37M

This table details how cash moves in and out of Sotera Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-34	39	4.47	289	-95	-23	68
Net Cash From Operating Activities	149	121	282	278	-148	224	287
Net Cash From Continuing Operating Activities	149	121	282	278	-148	224	287
Net Income / (Loss) Continuing Operations	-20	-37	117	-234	51	44	78
Consolidated Net Income / (Loss)	-20	-37	117	-234	51	44	78
Depreciation Expense	67	63	64	64	77	84	95
Amortization Expense	88	92	93	87	90	87	47
Non-Cash Adjustments To Reconcile Net Income	42	41	25	430	-337	4.88	74
Changes in Operating Assets and Liabilities, net	-27	-38	-18	-70	-29	4.01	-6.80
Net Cash From Investing Activities	-57	-159	-160	-182	-215	-179	-135
Net Cash From Continuing Investing Activities	-57	-159	-160	-182	-215	-179	-135
Purchase of Property, Plant & Equipment	-57	-54	-102	-182	-215	-179	-138
Other Investing Activities, net	0.00	0.00	-0.70	0.03	0.07	0.07	2.87
Net Cash From Financing Activities	-126	73	-117	198	266	-51	-101
Net Cash From Continuing Financing Activities	-126	73	-117	198	266	-51	-101
Repayment of Debt	-2,579	-1,199	-107	-1.85	-230	-2,299	-94
Issuance of Debt	3,145	150	0.00	200	500	2,259	0.00
Other Financing Activities, net	0.00	0.00	-1.43	-0.39	-4.09	-11	-6.57
Effect of Exchange Rate Changes	0.49	4.11	0.04	-4.46	2.04	-17	16
Cash Interest Paid	151	211	59	76	174	180	164
Cash Income Taxes Paid	45	24	52	75	50	66	61

This table details how cash moves in and out of Sotera Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	49	-39	-15	61	-30	27	28	-33	45	-31	41
Net Cash From Operating Activities	113	9.70	61	97	56	56	57	71	103	29	88
Net Cash From Continuing Operating Activities	113	9.70	61	97	56	56	57	71	103	29	88
Net Income / (Loss) Continuing Operations	39	6.32	8.75	17	12	-13	7.96	48	35	27	54
Consolidated Net Income / (Loss)	39	6.32	8.75	17	12	-13	7.96	48	35	27	54
Depreciation Expense	21	20	20	23	21	22	23	23	27	25	28
Amortization Expense	23	23	22	21	21	20	13	6.95	7.04	7.07	7.19
Non-Cash Adjustments To Reconcile Net Income	11	-32	31	11	-4.80	43	70	-33	9.06	-23	5.64
Changes in Operating Assets and Liabilities, net	20	-7.84	-20	25	6.60	-16	-57	26	25	-6.74	-5.81
Net Cash From Investing Activities	-65	-35	-42	-36	-66	-20	-31	-33	-51	-45	-43
Net Cash From Continuing Investing Activities	-65	-35	-42	-36	-66	-20	-31	-33	-51	-45	-43
Purchase of Property, Plant & Equipment	-65	-35	-42	-36	-66	-20	-31	-36	-51	-46	-46
Other Investing Activities, net	-	0.04	-	0.04	-	0.04	-	2.84	-	1.04	3.15
Net Cash From Financing Activities	-3.79	-12	-29	-2.65	-6.55	-8.09	-6.93	-77	-8.18	-13	-2.41
Net Cash From Continuing Financing Activities	-3.79	-12	-29	-2.65	-6.55	-8.09	-6.93	-77	-8.18	-13	-2.41
Repayment of Debt	0.30	-3.05	-2,289	-2.65	-2.12	-4.49	-6.88	-77	-5.47	-3.98	-2.13
Other Financing Activities, net	-4.09	-8.89	-	-	-4.43	-3.60	-0.05	-0.21	-2.71	-8.80	-0.27
Effect of Exchange Rate Changes	4.62	-1.74	-5.02	2.28	-13	-0.34	8.94	6.27	1.20	-2.04	-2.01
Cash Interest Paid	23	70	41	32	37	47	55	27	34	37	49
Cash Income Taxes Paid	7.62	9.84	18	15	23	12	20	15	13	9.20	15

This table presents Sotera Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	2,761	2,790	3,118	3,130	3,072	3,263
Total Current Assets	315	346	645	557	526	613
Cash & Equivalents	102	107	395	296	277	345
Restricted Cash	0.01	0.01	1.08	5.25	1.62	1.84
Accounts Receivable	92	108	118	148	140	139
Inventories, net	34	54	37	48	49	54
Prepaid Expenses	65	72	81	54	51	65
Current Deferred & Refundable Income Taxes	22	4.64	12	5.73	6.66	8.00
Plant, Property, & Equipment, net	610	651	775	947	1,037	1,131
Total Noncurrent Assets	1,836	1,793	1,698	1,626	1,509	1,519
Goodwill	1,116	1,120	1,102	1,111	1,081	1,103
Intangible Assets	643	599	491	416	318	288
Noncurrent Deferred & Refundable Income Taxes	8.42	5.89	4.10	4.99	2.87	3.85
Employee Benefit Assets	0.00	5.48	36	28	43	54
Other Noncurrent Operating Assets	55	53	65	65	65	70
Total Liabilities & Shareholders' Equity	2,761	2,790	3,118	3,130	3,072	3,263
Total Liabilities	2,307	2,203	2,767	2,687	2,667	2,657
Total Current Liabilities	141	161	792	231	191	250
Short-Term Debt	-	9.29	205	11	20	20
Accounts Payable	52	73	74	71	55	78
Accrued Expenses	61	62	490	122	90	125
Current Deferred Revenue	6.06	8.67	12	13	15	18
Current Deferred & Payable Income Tax Liabilities	10	6.70	5.87	4.15	7.56	5.69
Other Current Liabilities	11	1.78	4.62	8.77	2.92	3.47
Total Noncurrent Liabilities	2,152	2,042	1,976	2,456	2,476	2,408
Long-Term Debt	1,825	1,744	1,747	2,224	2,208	2,127
Capital Lease Obligations	-	41	57	64	95	94
Asset Retirement Reserve & Litigation Obligation	45	42	43	48	49	53
Noncurrent Deferred Revenue	21	21	19	19	17	17
Noncurrent Deferred & Payable Income Tax Liabilities	122	135	68	64	70	71
Noncurrent Employee Benefit Liabilities	48	11	7.91	8.44	7.86	8.12
Other Noncurrent Operating Liabilities	91	49	34	29	29	37
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	455	586	350	444	405	606
Total Preferred & Common Equity	452	586	350	444	405	606
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	452	586	350	444	405	606
Common Stock	1,169	1,175	1,192	1,218	1,247	1,265
Retained Earnings	-589	-472	-706	-654	-610	-532
Treasury Stock	-34	-34	-30	-27	-23	-17
Accumulated Other Comprehensive Income / (Loss)	-94	-84	-107	-93	-208	-110

This table presents Sotera Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	3,414	3,075	3,037	3,060	3,058	3,149	3,098	3,217	3,186	3,236	3,307
Total Current Assets	924	547	520	487	498	564	555	608	578	586	646
Cash & Equivalents	648	263	245	261	246	307	304	332	299	314	357
Restricted Cash	12	7.79	7.58	1.69	1.67	1.74	1.69	1.84	1.83	1.80	0.01
Accounts Receivable	109	117	118	111	124	130	128	137	142	137	151
Inventories, net	47	42	38	51	58	54	61	60	50	57	56
Prepaid Expenses	87	91	84	54	57	57	55	66	72	69	75
Current Deferred & Refundable Income Taxes	20	26	27	8.29	12	14	5.14	11	12	6.31	8.08
Plant, Property, & Equipment, net	816	859	884	979	995	1,026	1,046	1,080	1,094	1,143	1,168
Total Noncurrent Assets	1,674	1,669	1,633	1,593	1,566	1,559	1,496	1,528	1,514	1,506	1,493
Goodwill	1,103	1,110	1,101	1,103	1,098	1,105	1,084	1,105	1,099	1,098	1,091
Intangible Assets	472	456	429	390	368	352	300	300	291	279	270
Noncurrent Deferred & Refundable Income Taxes	4.17	4.16	4.04	4.88	4.75	4.95	2.98	4.47	3.22	3.77	3.74
Employee Benefit Assets	37	39	39	30	31	33	44	48	49	55	56
Other Noncurrent Operating Assets	58	59	59	65	64	65	64	71	72	71	72
Total Liabilities & Shareholders' Equity	3,414	3,075	3,037	3,060	3,058	3,149	3,098	3,217	3,186	3,236	3,307
Total Liabilities	3,053	2,657	2,659	2,630	2,635	2,679	2,683	2,705	2,636	2,613	2,641
Total Current Liabilities	600	200	201	152	170	196	226	246	242	208	231
Short-Term Debt	20	12	12	10	16	20	20	20	20	20	19
Accounts Payable	62	56	57	62	64	71	70	64	61	77	101
Accrued Expenses	497	103	106	62	69	83	114	144	140	86	84
Current Deferred Revenue	15	14	13	13	13	11	14	12	14	14	14
Current Deferred & Payable Income Tax Liabilities	4.59	5.73	4.14	4.51	4.41	8.34	5.39	3.94	4.32	8.40	9.31
Other Current Liabilities	2.11	9.40	8.65	1.49	2.77	2.82	3.04	3.24	3.35	3.58	3.73
Total Noncurrent Liabilities	2,453	2,456	2,459	2,478	2,465	2,483	2,457	2,459	2,393	2,406	2,410
Long-Term Debt	2,222	2,222	2,223	2,225	2,214	2,211	2,205	2,203	2,129	2,124	2,126
Capital Lease Obligations	82	61	84	91	94	98	94	95	95	93	92
Asset Retirement Reserve & Litigation Obligation	43	44	44	48	48	49	50	52	52	54	54
Noncurrent Deferred Revenue	19	19	18	18	18	18	17	17	17	17	16
Noncurrent Deferred & Payable Income Tax Liabilities	63	68	69	60	54	64	54	48	54	75	82
Noncurrent Employee Benefit Liabilities	7.86	8.01	7.76	8.24	8.18	8.22	7.91	8.30	8.12	7.98	7.74
Other Noncurrent Operating Liabilities	15	33	12	28	30	35	29	35	38	35	33
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	361	418	377	429	423	470	414	511	550	623	666
Total Preferred & Common Equity	361	418	377	429	423	470	414	511	550	623	666
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	361	418	377	429	423	470	414	511	550	623	666
Common Stock	1,198	1,206	1,213	1,223	1,232	1,242	1,248	1,254	1,262	1,266	1,270
Retained Earnings	-703	-679	-693	-648	-639	-622	-623	-615	-567	-506	-452
Treasury Stock	-29	-29	-28	-26	-25	-25	-21	-19	-19	-12	-9.29
Accumulated Other Comprehensive Income / (Loss)	-105	-79	-114	-120	-145	-125	-189	-108	-126	-126	-143

This table displays calculated financial ratios and metrics derived from Sotera Health's official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	5.12%	13.85%	-100.00%	0.00%	4.88%	5.74%
EBITDA Growth	0.00%	9.90%	13.78%	-5.09%	11.09%	5.04%	-5.65%
EBIT Growth	0.00%	18.01%	22.63%	-5.89%	11.49%	6.63%	0.65%
NOPAT Growth	0.00%	12.21%	18.66%	1.59%	-22.88%	-13.45%	64.87%
Net Income Growth	0.00%	-83.55%	412.40%	-420.57%	123.01%	-48.60%	75.57%
EPS Growth	0.00%	-77.78%	356.25%	-302.44%	121.69%	-11.11%	68.75%
Operating Cash Flow Growth	0.00%	-19.09%	133.48%	-1.27%	-153.15%	251.74%	28.12%
Free Cash Flow Firm Growth	0.00%	0.00%	104.20%	456.08%	-172.38%	131.16%	31.50%
Invested Capital Growth	0.00%	0.00%	3.94%	-13.29%	24.33%	0.37%	2.06%
Revenue Q/Q Growth	0.00%	0.00%	2.69%	-100.00%	5.92%	-1.79%	1.15%
EBITDA Q/Q Growth	0.00%	0.00%	4.23%	-3.38%	1,123.75%	-4.70%	2.67%
EBIT Q/Q Growth	0.00%	0.00%	6.72%	-4.71%	238.05%	-6.69%	6.73%
NOPAT Q/Q Growth	0.00%	0.00%	53.03%	8.52%	-17.74%	-29.82%	50.98%
Net Income Q/Q Growth	0.00%	0.00%	210.35%	-407.38%	128.13%	-37.25%	40.64%
EPS Q/Q Growth	0.00%	0.00%	272.73%	-293.02%	116.36%	-36.00%	35.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	18.78%	14.68%	7.05%	-20.39%	19.76%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	420.01%	-1,074.23%	-9.34%	12.84%
Invested Capital Q/Q Growth	0.00%	0.00%	3.73%	-12.81%	-0.12%	-1.66%	0.30%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	50.81%	54.22%	55.68%	0.00%	55.00%	54.73%	55.48%
EBITDA Margin	43.94%	45.94%	45.91%	0.00%	42.97%	43.04%	38.40%
Operating Margin	23.59%	25.18%	27.56%	0.00%	26.37%	27.05%	31.11%
EBIT Margin	24.02%	26.97%	29.05%	0.00%	27.06%	27.51%	26.18%
Profit (Net Income) Margin	-2.62%	-4.58%	12.57%	0.00%	8.23%	4.03%	6.70%
Tax Burden Percent	2,229.80%	96.48%	66.65%	154.44%	81.47%	38.99%	52.84%
Interest Burden Percent	-0.49%	-17.61%	64.94%	-95.47%	37.35%	37.62%	48.41%
Effective Tax Rate	0.00%	0.00%	33.35%	0.00%	51.54%	61.01%	47.16%
Return on Invested Capital (ROIC)	0.00%	13.24%	7.71%	0.00%	6.09%	4.75%	7.73%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-7.85%	4.53%	0.00%	3.45%	1.20%	1.97%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-29.74%	14.80%	0.00%	15.67%	5.72%	7.69%
Return on Equity (ROE)	0.00%	-16.50%	22.51%	-80.20%	21.76%	10.46%	15.42%
Cash Return on Invested Capital (CROIC)	0.00%	-186.76%	3.84%	22.46%	-15.60%	4.38%	5.69%
Operating Return on Assets (OROA)	0.00%	7.99%	9.75%	0.00%	9.09%	9.76%	9.62%
Return on Assets (ROA)	0.00%	-1.36%	4.22%	0.00%	2.76%	1.43%	2.46%
Return on Common Equity (ROCE)	0.00%	-16.41%	22.46%	-80.20%	21.76%	10.46%	15.42%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-8.29%	19.98%	-107.20%	19.47%	10.96%	0.00%
Net Operating Profit after Tax (NOPAT)	129	144	171	174	134	116	191
NOPAT Margin	16.51%	17.63%	18.37%	0.00%	12.78%	10.54%	16.44%
Net Nonoperating Expense Percent (NNEP)	0.00%	21.09%	3.18%	33.39%	2.64%	3.55%	5.76%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	7.37%	4.89%	4.25%	6.72%
Cost of Revenue to Revenue	49.19%	45.78%	44.32%	0.00%	45.00%	45.27%	44.52%
SG&A Expenses to Revenue	18.95%	21.82%	21.27%	0.00%	22.56%	22.05%	21.72%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.22%	29.04%	28.12%	0.00%	28.64%	27.69%	24.36%
Earnings before Interest and Taxes (EBIT)	187	221	271	255	284	303	305
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	342	376	428	406	451	474	447
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.83	11.37	6.71	10.73	9.57	8.27
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.38	1.56	7.15	0.00	4.54	3.52	4.31
Price to Earnings (P/E)	0.00	0.00	57.00	0.00	92.69	87.27	64.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	1.75%	0.00%	1.08%	1.15%	1.56%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.37	3.68	2.02	2.77	2.42	2.76
Enterprise Value to Revenue (EV/Rev)	0.00	3.65	8.95	0.00	6.44	5.38	5.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	7.96	19.50	9.76	14.99	12.50	15.45
Enterprise Value to EBIT (EV/EBIT)	0.00	13.55	30.82	15.56	23.81	19.55	22.66
Enterprise Value to NOPAT (EV/NOPAT)	0.00	20.73	48.74	22.79	50.41	51.01	36.09
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	24.79	29.62	14.26	0.00	26.41	24.04
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	97.71	8.35	0.00	55.30	49.06
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	4.01	3.06	5.74	5.18	5.74	3.70
Long-Term Debt to Equity	0.00	4.01	3.04	5.15	5.16	5.69	3.66
Financial Leverage	0.00	3.79	3.27	3.51	4.55	4.76	3.90
Leverage Ratio	0.00	6.07	5.33	6.31	7.87	7.31	6.27
Compound Leverage Factor	0.00	-1.07	3.46	-6.02	2.94	2.75	3.03
Debt to Total Capital	0.00%	80.06%	75.37%	85.15%	83.82%	85.16%	78.71%
Short-Term Debt to Total Capital	0.00%	0.00%	0.39%	8.68%	0.39%	0.73%	0.69%
Long-Term Debt to Total Capital	0.00%	80.06%	74.98%	76.48%	83.43%	84.43%	78.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	19.84%	24.63%	14.85%	16.18%	14.84%	21.29%
Debt to EBITDA	0.00	4.86	4.19	4.95	5.10	4.91	5.01
Net Debt to EBITDA	0.00	4.55	3.92	3.97	4.43	4.32	4.24
Long-Term Debt to EBITDA	0.00	4.86	4.17	4.44	5.07	4.86	4.97
Debt to NOPAT	0.00	12.65	10.48	11.55	17.14	20.02	11.71
Net Debt to NOPAT	0.00	11.85	9.80	9.28	14.89	17.62	9.90
Long-Term Debt to NOPAT	0.00	12.65	10.43	10.38	17.06	19.85	11.61
Altman Z-Score	0.00	0.67	2.31	0.41	1.53	1.41	1.70
Noncontrolling Interest Sharing Ratio	0.00%	0.50%	0.22%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	2.24	2.15	0.81	2.42	2.75	2.46
Quick Ratio	0.00	1.38	1.33	0.65	1.93	2.19	1.94
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-2,033	85	475	-344	107	141
Operating Cash Flow to CapEx	260.30%	225.36%	275.59%	152.41%	-68.72%	125.18%	208.09%
Free Cash Flow to Firm to Interest Expense	0.00	-45.94	4.13	0.00	0.00	4.43	96.27
Operating Cash Flow to Interest Expense	4.94	2.72	13.61	0.00	0.00	9.28	196.44
Operating Cash Flow Less CapEx to Interest Expense	3.04	1.52	8.67	0.00	0.00	1.87	102.04
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.30	0.34	0.00	0.34	0.35	0.37
Accounts Receivable Turnover	0.00	8.92	9.32	0.00	7.88	7.64	8.32
Inventory Turnover	0.00	10.99	9.34	9.77	11.05	10.22	10.01
Fixed Asset Turnover	0.00	1.34	1.48	0.00	1.22	1.11	1.07
Accounts Payable Turnover	0.00	7.15	6.59	6.08	6.50	7.90	7.79
Days Sales Outstanding (DSO)	0.00	40.93	39.17	0.00	46.30	47.77	43.86
Days Inventory Outstanding (DIO)	0.00	33.22	39.07	37.36	33.03	35.71	36.47
Days Payable Outstanding (DPO)	0.00	51.06	55.38	60.06	56.12	46.21	46.87
Cash Conversion Cycle (CCC)	0.00	23.09	22.86	0.00	23.21	37.27	33.46
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	2,178	2,263	1,963	2,440	2,449	2,500
Invested Capital Turnover	0.00	0.75	0.42	0.00	0.48	0.45	0.47
Increase / (Decrease) in Invested Capital	0.00	2,178	86	-301	478	9.01	51
Enterprise Value (EV)	0.00	2,990	8,340	3,962	6,759	5,919	6,905
Market Capitalization	1,072	1,279	6,663	2,350	4,762	3,875	5,011
Book Value per Share	$0.00	$1.90	$2.07	$1.24	$1.57	$1.43	$2.13
Tangible Book Value per Share	$0.00	($5.50)	($4.00)	($4.41)	($3.83)	($3.51)	($2.76)
Total Capital	0.00	2,279	2,380	2,359	2,742	2,728	2,846
Total Debt	0.00	1,825	1,794	2,009	2,298	2,323	2,240
Total Long-Term Debt	0.00	1,825	1,784	1,804	2,287	2,303	2,221
Net Debt	0.00	1,709	1,677	1,612	1,997	2,044	1,894
Capital Expenditures (CapEx)	57	54	102	182	215	179	138
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	72	87	-338	36	76	37
Debt-free Net Working Capital (DFNWC)	0.00	174	194	58	337	355	384
Net Working Capital (NWC)	0.00	174	185	-147	327	335	364
Net Nonoperating Expense (NNE)	149	182	54	549	48	72	113
Net Nonoperating Obligations (NNO)	0.00	1,723	1,677	1,612	1,997	2,044	1,894
Total Depreciation and Amortization (D&A)	155	155	157	151	167	171	142
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	8.80%	9.36%	0.00%	3.40%	6.91%	3.19%
Debt-free Net Working Capital to Revenue	0.00%	21.32%	20.84%	0.00%	32.15%	32.25%	32.96%
Net Working Capital to Revenue	0.00%	21.32%	19.84%	0.00%	31.12%	30.45%	31.27%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.41	($0.83)	$0.18	$0.16	$0.27
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	279.23M	280.10M	281.01M	282.78M	283.96M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.41	($0.83)	$0.18	$0.16	$0.27
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	279.38M	280.10M	283.22M	284.91M	286.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	282.93M	282.42M	282.83M	283.47M	284.39M
Normalized Net Operating Profit after Tax (NOPAT)	133	144	171	174	194	208	191
Normalized NOPAT Margin	17.03%	17.63%	18.37%	0.00%	18.46%	18.93%	16.44%
Pre Tax Income Margin	-0.12%	-4.75%	18.86%	0.00%	10.10%	10.35%	12.68%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	6.20	4.99	13.08	0.00	0.00	12.53	208.41
NOPAT to Interest Expense	4.26	3.26	8.27	0.00	0.00	4.80	130.86
EBIT Less CapEx to Interest Expense	4.30	3.78	8.14	0.00	0.00	5.12	114.00
NOPAT Less CapEx to Interest Expense	2.36	2.05	3.33	0.00	0.00	-2.61	36.46
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	-3,383.94%	0.00%	7.19%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3,383.94%	-90.69%	7.19%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sotera Health's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	284,392,079.00	285,166,994.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	284,392,079.00	285,166,994.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	0.09	0.19
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	141.25%	12.51%	8.35%	8.47%	-6.46%	2.56%	6.42%	9.05%	4.56%	10.03%	9.18%
EBITDA Growth	87.23%	26.45%	13.12%	57.58%	-31.28%	-28.85%	-20.60%	10.97%	9.08%	60.93%	54.57%
EBIT Growth	132.04%	54.02%	21.03%	105.36%	-39.56%	-50.64%	-24.45%	34.09%	22.19%	196.93%	90.17%
NOPAT Growth	45.48%	73.90%	3.03%	101.45%	-61.02%	-40.15%	-48.35%	130.50%	252.51%	18.49%	96.99%
Net Income Growth	115.96%	122.48%	-62.77%	224.44%	-83.28%	-309.71%	-9.05%	184.74%	182.78%	300.52%	573.74%
EPS Growth	112.28%	100.00%	-62.50%	220.00%	-64.29%	-350.00%	0.00%	183.33%	140.00%	280.00%	533.33%
Operating Cash Flow Growth	10.99%	-71.36%	118.21%	132.87%	-50.75%	472.44%	-6.33%	-26.99%	85.05%	-46.98%	54.13%
Free Cash Flow Firm Growth	-221.41%	-232.50%	89.29%	99.36%	103.57%	119.00%	351.85%	569.57%	126.07%	-166.03%	-40.92%
Invested Capital Growth	24.33%	23.06%	2.23%	1.94%	0.37%	-2.60%	-0.10%	0.08%	2.06%	4.79%	2.00%
Revenue Q/Q Growth	17.88%	-20.00%	11.45%	3.21%	1.66%	-12.29%	15.64%	5.77%	-2.53%	-7.71%	14.76%
EBITDA Q/Q Growth	128.42%	-36.83%	26.30%	6.44%	-0.39%	-46.86%	40.94%	48.76%	-2.09%	-21.60%	35.37%
EBIT Q/Q Growth	248.74%	-51.27%	49.53%	6.93%	2.64%	-69.92%	128.87%	89.79%	-6.48%	-26.91%	46.58%
NOPAT Q/Q Growth	102.77%	-50.18%	45.45%	-27.91%	-25.38%	-23.50%	25.52%	221.70%	14.12%	-43.80%	55.13%
Net Income Q/Q Growth	639.39%	-83.65%	38.45%	94.17%	-27.50%	-207.60%	160.05%	507.89%	-28.00%	-23.70%	101.75%
EPS Q/Q Growth	380.00%	-85.71%	50.00%	100.00%	-16.67%	-200.00%	160.00%	466.67%	-29.41%	-25.00%	111.11%
Operating Cash Flow Q/Q Growth	170.31%	-91.43%	531.97%	58.99%	-42.83%	-0.35%	3.41%	23.93%	44.90%	-71.45%	200.65%
Free Cash Flow Firm Q/Q Growth	82.68%	-4.85%	97.69%	-51.57%	197.27%	457.79%	-69.38%	182.61%	-53.17%	-305.45%	133.98%
Invested Capital Q/Q Growth	-0.12%	2.13%	0.23%	-0.30%	-1.66%	-0.89%	2.80%	-0.12%	0.30%	1.76%	0.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	58.05%	51.22%	55.24%	55.36%	56.64%	53.21%	56.61%	57.04%	54.68%	52.52%	55.38%
EBITDA Margin	60.14%	38.58%	43.72%	45.09%	44.18%	26.77%	32.62%	45.88%	46.09%	39.15%	46.18%
Operating Margin	33.53%	21.43%	27.77%	28.20%	30.03%	10.25%	18.49%	35.71%	56.13%	27.08%	33.23%
EBIT Margin	46.20%	21.27%	28.54%	29.56%	29.85%	10.24%	20.26%	36.35%	34.88%	27.62%	35.28%
Profit (Net Income) Margin	23.75%	2.55%	3.16%	5.95%	4.25%	-5.21%	2.71%	15.55%	11.48%	9.49%	16.69%
Tax Burden Percent	112.20%	57.41%	57.81%	39.76%	27.41%	89.46%	42.13%	66.36%	49.43%	62.40%	68.73%
Interest Burden Percent	45.82%	20.87%	19.18%	50.66%	51.91%	-56.90%	31.69%	64.45%	66.61%	55.09%	68.83%
Effective Tax Rate	41.10%	42.59%	42.19%	60.24%	72.59%	0.00%	57.87%	33.64%	50.57%	37.60%	31.27%
Return on Invested Capital (ROIC)	9.41%	5.86%	7.13%	5.09%	3.70%	3.23%	3.51%	10.94%	13.05%	8.08%	11.02%
ROIC Less NNEP Spread (ROIC-NNEP)	10.10%	4.57%	5.40%	4.36%	3.13%	1.68%	2.77%	9.66%	10.54%	7.03%	10.00%
Return on Net Nonoperating Assets (RNNOA)	45.91%	21.52%	26.31%	21.01%	14.91%	8.13%	12.05%	37.51%	41.06%	26.68%	32.82%
Return on Equity (ROE)	55.33%	27.39%	33.44%	26.10%	18.62%	11.36%	15.56%	48.45%	54.11%	34.76%	43.84%
Cash Return on Invested Capital (CROIC)	-15.60%	-14.23%	3.25%	4.79%	4.38%	5.73%	2.70%	5.01%	5.69%	4.12%	7.82%
Operating Return on Assets (OROA)	15.52%	7.08%	10.22%	10.71%	10.59%	3.68%	7.26%	13.20%	12.81%	10.37%	13.16%
Return on Assets (ROA)	7.98%	0.85%	1.13%	2.16%	1.51%	-1.87%	0.97%	5.65%	4.22%	3.57%	6.22%
Return on Common Equity (ROCE)	55.33%	27.39%	33.44%	26.10%	18.62%	11.36%	15.56%	48.45%	54.11%	34.76%	43.84%
Return on Equity Simple (ROE_SIMPLE)	0.00%	12.78%	9.48%	15.05%	0.00%	5.99%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	61	31	44	32	24	18	23	74	84	47	73
NOPAT Margin	19.75%	12.30%	16.05%	11.21%	8.23%	7.18%	7.79%	23.70%	27.75%	16.89%	22.84%
Net Nonoperating Expense Percent (NNEP)	-0.69%	1.30%	1.74%	0.73%	0.57%	1.55%	0.74%	1.28%	2.51%	1.05%	1.02%
Return On Investment Capital (ROIC_SIMPLE)	2.23%	-	-	-	0.88%	0.67%	0.81%	2.64%	2.96%	1.65%	2.53%
Cost of Revenue to Revenue	41.95%	48.78%	44.76%	44.64%	43.36%	46.79%	43.39%	42.96%	45.32%	47.48%	44.62%
SG&A Expenses to Revenue	19.46%	23.45%	21.90%	21.72%	21.31%	24.78%	23.41%	20.33%	18.95%	24.36%	21.21%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	24.52%	29.79%	27.47%	27.15%	26.61%	42.96%	38.12%	21.32%	-1.45%	25.44%	22.15%
Earnings before Interest and Taxes (EBIT)	143	53	79	84	87	26	60	113	106	77	113
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	187	96	121	129	128	68	96	143	140	110	148
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	10.73	7.90	7.95	10.06	9.57	7.98	6.17	8.12	8.27	6.55	7.60
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.54	3.15	3.06	4.22	3.52	2.99	2.81	3.88	4.31	3.43	4.16
Price to Earnings (P/E)	92.69	61.88	83.80	66.84	87.27	133.20	131.39	80.61	64.29	34.62	30.96
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.08%	1.62%	1.19%	1.50%	1.15%	0.75%	0.76%	1.24%	1.56%	2.89%	3.23%
Enterprise Value to Invested Capital (EV/IC)	2.77	2.19	2.18	2.71	2.42	2.19	2.06	2.57	2.76	2.36	2.73
Enterprise Value to Revenue (EV/Rev)	6.44	5.07	4.95	6.02	5.38	4.81	4.57	5.57	5.93	5.05	5.71
Enterprise Value to EBITDA (EV/EBITDA)	14.99	12.52	12.08	13.58	12.50	11.93	12.21	14.73	15.45	12.29	12.84
Enterprise Value to EBIT (EV/EBIT)	23.81	20.41	19.33	20.81	19.55	19.27	20.03	22.45	22.66	16.85	16.94
Enterprise Value to NOPAT (EV/NOPAT)	50.41	37.46	40.34	40.82	51.01	69.74	79.15	50.59	36.09	27.41	28.09
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	24.05	23.97	26.41	19.70	19.32	26.73	24.04	22.98	23.76
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	67.74	57.18	55.30	37.74	76.25	51.39	49.06	58.53	35.21
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	5.18	5.42	5.49	4.95	5.74	5.60	4.53	4.07	3.70	3.59	3.36
Long-Term Debt to Equity	5.16	5.39	5.46	4.91	5.69	5.55	4.49	4.04	3.66	3.56	3.33
Financial Leverage	4.55	4.71	4.87	4.82	4.76	4.83	4.35	3.88	3.90	3.80	3.28
Leverage Ratio	7.87	8.19	7.29	7.30	7.31	7.30	6.72	6.21	6.27	6.11	5.54
Compound Leverage Factor	3.61	1.71	1.40	3.70	3.79	-4.15	2.13	4.00	4.17	3.37	3.82
Debt to Total Capital	83.82%	84.41%	84.60%	83.20%	85.16%	84.85%	81.93%	80.29%	78.71%	78.23%	77.06%
Short-Term Debt to Total Capital	0.39%	0.37%	0.58%	0.72%	0.73%	0.73%	0.72%	0.70%	0.69%	0.69%	0.67%
Long-Term Debt to Total Capital	83.43%	84.05%	84.02%	82.49%	84.43%	84.12%	81.21%	79.59%	78.02%	77.54%	76.40%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	16.18%	15.59%	15.40%	16.80%	14.84%	15.15%	18.07%	19.71%	21.29%	21.77%	22.94%
Debt to EBITDA	5.10	5.34	5.16	4.69	4.91	5.20	5.51	5.15	5.01	4.58	4.14
Net Debt to EBITDA	4.43	4.73	4.61	4.07	4.32	4.51	4.71	4.46	4.24	3.93	3.48
Long-Term Debt to EBITDA	5.07	5.31	5.13	4.65	4.86	5.16	5.46	5.11	4.97	4.54	4.10
Debt to NOPAT	17.14	15.96	17.24	14.08	20.02	30.41	35.70	17.70	11.71	10.22	9.05
Net Debt to NOPAT	14.89	14.16	15.40	12.22	17.62	26.40	30.55	15.33	9.90	8.78	7.61
Long-Term Debt to NOPAT	17.06	15.89	17.12	13.96	19.85	30.15	35.38	17.55	11.61	10.13	8.97
Altman Z-Score	1.38	1.02	1.05	1.37	1.18	0.97	0.98	1.37	1.50	1.30	1.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.42	3.20	2.93	2.88	2.75	2.46	2.47	2.38	2.46	2.82	2.80
Quick Ratio	1.93	2.44	2.18	2.23	2.19	1.91	1.90	1.82	1.94	2.17	2.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-416	-436	-10	-15	15	83	25	72	34	-69	23
Operating Cash Flow to CapEx	174.50%	27.80%	146.22%	267.81%	84.59%	278.75%	183.85%	196.71%	203.37%	63.76%	190.52%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-0.43	-218.40	0.00	0.00	317.53	66.04	0.00	0.00	25.08
Operating Cash Flow to Interest Expense	0.00	0.00	2.62	1,392.19	0.00	0.00	717.70	65.46	0.00	0.00	94.55
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.83	872.34	0.00	0.00	327.34	32.18	0.00	0.00	44.92
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.33	0.36	0.36	0.35	0.36	0.36	0.36	0.37	0.38	0.37
Accounts Receivable Turnover	7.88	9.78	9.11	9.02	7.64	9.26	8.64	8.44	8.32	8.96	8.47
Inventory Turnover	11.05	9.87	9.85	10.97	10.22	8.83	8.49	9.78	10.01	8.98	9.42
Fixed Asset Turnover	1.22	1.20	1.18	1.17	1.11	1.09	1.08	1.09	1.07	1.09	1.08
Accounts Payable Turnover	6.50	7.84	8.20	7.86	7.90	7.54	7.81	7.66	7.79	7.25	6.65
Days Sales Outstanding (DSO)	46.30	37.32	40.04	40.48	47.77	39.43	42.23	43.23	43.86	40.72	43.08
Days Inventory Outstanding (DIO)	33.03	36.97	37.07	33.26	35.71	41.34	43.00	37.30	36.47	40.67	38.76
Days Payable Outstanding (DPO)	56.12	46.56	44.52	46.45	46.21	48.43	46.77	47.62	46.87	50.36	54.88
Cash Conversion Cycle (CCC)	23.21	27.73	32.59	27.29	37.27	32.33	38.46	32.91	33.46	31.03	26.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,440	2,492	2,498	2,491	2,449	2,427	2,496	2,493	2,500	2,544	2,545
Invested Capital Turnover	0.48	0.48	0.44	0.45	0.45	0.45	0.45	0.46	0.47	0.48	0.48
Increase / (Decrease) in Invested Capital	478	467	54	47	9.01	-65	-2.47	1.99	51	116	50
Enterprise Value (EV)	6,759	5,457	5,435	6,750	5,919	5,319	5,141	6,410	6,905	6,000	6,941
Market Capitalization	4,762	3,394	3,360	4,730	3,875	3,305	3,156	4,468	5,011	4,078	5,062
Book Value per Share	$1.57	$1.52	$1.49	$1.66	$1.43	$1.46	$1.80	$1.94	$2.13	$2.19	$2.33
Tangible Book Value per Share	($3.83)	($3.77)	($3.69)	($3.48)	($3.51)	($3.42)	($3.15)	($2.96)	($2.76)	($2.65)	($2.44)
Total Capital	2,742	2,755	2,746	2,799	2,728	2,734	2,830	2,794	2,846	2,860	2,902
Total Debt	2,298	2,326	2,323	2,329	2,323	2,319	2,318	2,243	2,240	2,237	2,237
Total Long-Term Debt	2,287	2,315	2,307	2,309	2,303	2,300	2,298	2,224	2,221	2,218	2,217
Net Debt	1,997	2,063	2,075	2,020	2,044	2,013	1,984	1,942	1,894	1,921	1,880
Capital Expenditures (CapEx)	65	35	42	36	66	20	31	36	51	46	46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	36	82	96	80	76	43	48	54	37	82	78
Debt-free Net Working Capital (DFNWC)	337	345	344	388	355	349	382	355	384	398	435
Net Working Capital (NWC)	327	335	328	368	335	329	362	335	364	378	415
Net Nonoperating Expense (NNE)	-12	24	36	15	12	32	15	25	49	21	20
Net Nonoperating Obligations (NNO)	1,997	2,063	2,075	2,020	2,044	2,013	1,984	1,942	1,894	1,921	1,880
Total Depreciation and Amortization (D&A)	43	43	42	44	42	42	36	30	34	32	35
Debt-free, Cash-free Net Working Capital to Revenue	3.40%	7.63%	8.76%	7.11%	6.91%	3.87%	4.27%	4.69%	3.19%	6.90%	6.40%
Debt-free Net Working Capital to Revenue	32.15%	32.03%	31.32%	34.64%	32.25%	31.52%	33.99%	30.86%	32.96%	33.46%	35.74%
Net Working Capital to Revenue	31.12%	31.09%	29.87%	32.85%	30.45%	29.73%	32.18%	29.16%	31.27%	31.80%	34.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09	$0.19
Adjusted Weighted Average Basic Shares Outstanding	281.01M	281.91M	282.89M	283.06M	282.78M	283.56M	283.93M	284.07M	283.96M	284.89M	285.77M
Adjusted Diluted Earnings per Share	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09	$0.19
Adjusted Weighted Average Diluted Shares Outstanding	283.22M	284.06M	284.54M	285.56M	284.91M	283.56M	285.76M	286.75M	286.42M	287.62M	288.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	282.83M	283.07M	283.21M	283.24M	283.47M	283.86M	284.05M	284.09M	284.39M	285.17M	285.37M
Normalized Net Operating Profit after Tax (NOPAT)	61	31	44	56	61	40	62	74	119	47	73
Normalized NOPAT Margin	19.75%	12.30%	16.05%	19.74%	21.02%	15.69%	21.03%	23.70%	39.29%	16.89%	22.84%
Pre Tax Income Margin	21.17%	4.44%	5.47%	14.98%	15.49%	-5.82%	6.42%	23.43%	23.23%	15.22%	24.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	3.37	1,205.66	0.00	0.00	745.35	104.11	0.00	0.00	121.15
NOPAT to Interest Expense	0.00	0.00	1.90	457.25	0.00	0.00	286.67	67.87	0.00	0.00	78.41
EBIT Less CapEx to Interest Expense	0.00	0.00	1.58	685.81	0.00	0.00	354.99	70.83	0.00	0.00	71.52
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.11	-62.59	0.00	0.00	-103.70	34.60	0.00	0.00	28.79
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Sotera Health (NASDAQ: SHC) showed a mixed but improving operating picture in Q1 2026, with solid revenue and profit growth versus late 2025, but leverage remains the biggest risk on the balance sheet.

For the quarter ended March 31, 2026, revenue came in at $280.0 million, up from $303.4 million in Q4 2025 but slightly below the stronger quarters seen in 2025. Gross profit was $147.1 million, and operating income was $75.8 million, producing an operating margin of about 27%. Net income was $26.6 million, or $0.09 per share.

Cash generation was softer than earnings suggest. The company produced $29.4 million of operating cash flow in Q1 2026, down sharply from $103.1 million in Q4 2025 and $55.5 million in Q1 2025. Capital spending remained meaningful at $46.2 million, and debt repayment plus other financing items also consumed cash.

The balance sheet still carries a heavy debt load. Sotera Health ended Q1 2026 with:

Cash and equivalents of $314.1 million, plus $1.8 million of restricted cash.
Total current assets of $586.0 million, giving the company a decent short-term liquidity base.
Total assets of $3.24 billion, supported by a large installed asset base and substantial goodwill/intangibles.
Total liabilities of $2.61 billion, including $2.12 billion of long-term debt.
Total common equity of only $622.5 million, reflecting a highly leveraged capital structure.

Looking at the last four years, the trend is broadly positive on operations but less impressive on cash and leverage:

Revenue has generally grown from the low-$220 million range in early 2023 to roughly $280 million in Q1 2026.
Operating income has improved materially from the weak periods in 2023 and 2024, showing better cost control and stronger gross profit conversion.
The company has stayed profitable in recent quarters, a notable turnaround from the heavy losses seen in parts of 2022 and 2023.
Depreciation and amortization remain significant non-cash expenses, which makes reported earnings look better than cash flow in some periods.
The share count has been fairly stable, with diluted shares around 287.6 million in Q1 2026 versus 283.6 million in Q1 2025.
Interest and other non-operating expenses have been a persistent drag on pre-tax results, especially when rates or financing costs spike.
Equity has trended lower over time as retained earnings remain negative and AOCI losses are substantial.

Bottom line: SHC is showing better core profitability than it did a few years ago, and the business continues to generate positive operating cash flow. However, the stock still carries balance-sheet risk because of its large debt burden and the company’s sensitivity to interest expense. For investors, the key question is whether Sotera can keep converting its improving operating performance into stronger free cash flow and gradual deleveraging.

08/21/26 06:34 AM ETAI Generated. May Contain Errors.

Sotera Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sotera Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Sotera Health's net income appears to be on a downward trend, with a most recent value of $77.95 million in 2025, falling from -$20.43 million in 2019. The previous period was $44.40 million in 2024. Check out Sotera Health's forecast to explore projected trends and price targets.

Sotera Health's total operating income in 2025 was $362.03 million, based on the following breakdown:

Total Gross Profit: $645.53 million
Total Operating Expenses: $283.50 million

Over the last 6 years, Sotera Health's total revenue changed from $778.33 million in 2019 to $1.16 billion in 2025, a change of 49.5%.

Sotera Health's total liabilities were at $2.66 billion at the end of 2025, a 0.4% decrease from 2024, and a 15.2% increase since 2020.

In the past 5 years, Sotera Health's cash and equivalents has ranged from $102.45 million in 2020 to $395.21 million in 2022, and is currently $344.62 million as of their latest financial filing in 2025.

Over the last 6 years, Sotera Health's book value per share changed from 0.00 in 2019 to 2.13 in 2025, a change of 213.3%.

Related Companies

Financial statements for NASDAQ:SHC last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sotera Health (SHC) Financials

Financials Breakdown Chart

Key Financial Trends

Sotera Health Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sotera Health (SHC) Financials

Annual Income Statements for Sotera Health

Quarterly Income Statements for Sotera Health

Annual Cash Flow Statements for Sotera Health

Quarterly Cash Flow Statements for Sotera Health

Annual Balance Sheets for Sotera Health

Quarterly Balance Sheets for Sotera Health

Annual Metrics And Ratios for Sotera Health

Quarterly Metrics And Ratios for Sotera Health

Financials Breakdown Chart

Key Financial Trends

Sotera Health Financials - Frequently Asked Questions

When does Sotera Health's financial year end?

How has Sotera Health's net income changed over the last 6 years?

What is Sotera Health's operating income?

How has Sotera Health's revenue changed over the last 6 years?

How much debt does Sotera Health have?

How much cash does Sotera Health have?

How has Sotera Health's book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools